/PRNewswire/ DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver.
Operator: Greetings, and welcome to the DURECT Corporation Second Quarter Earnings Call. [Operator Instructions]. It is now my pleasure to introduce your host, Tim Papp, Chief Financial Officer.
/PRNewswire/ DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate update..
Durect said Thursday it will offer about 3 million common shares and accompanying warrants with expected gross proceeds of about $15 million.
The securities will be sold at a combined purchase.